The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Projecting future complications of chronic hepatitis C in the United States
Open accessAbstract
Chronic hepatitis C virus (HCV) infection is common and often results in slowly progressive liver disease. Although acute hepatitis C is now uncommon, most patients with acute infection have developed chronic hepatitis, and, therefore, the pool of infected patients is large. We used a modification of a previously described natural history model for HCV infection to project the number of cases of HCV infection, cirrhosis, and liver failure over the next 40 years. The model estimated the prevalence of HCV infection in the United States was 3.07 × 10 6 in 1993 (compared with an adjusted National Health and Nutrition Evaluation Survey (NHANES) III estimate of 2.8 to 3.5 × 10 6). A gradual decline in the prevalence of infection should occur by year 2040 because of aging and natural deaths among the infected pool. However, as the duration of infection increases in the surviving cohort, the proportion with cirrhosis will increase from 16% to 32% by 2020 in an untreated population. Complications of cirrhosis also will increase dramatically over the next 20 years: hepatic decompensation (up 106%), hepatocellular carcinoma (up 81%), and liver-related deaths (up 180%). Although current treatment regimens eradicate HCV in over 50% of cases, many more patients would need to be treated to significantly impact disease progression. Identification and treatment of every case of HCV infection (with or without cirrhosis) would reduce the number of cases of decompensated cirrhosis by almost half after 20 years. Despite the declining incidence of acute HCV infection, chronic hepatitis C is common. The prevalence of cirrhosis and the incidence of its complications will increase over the next 10 to 20 years, because the duration of infection increases among those with chronic hepatitis C. These data emphasize the need for greater access to transplantation by expansion of the donor pool, increasing use of split livers and living donors, and novel options such as xenotransplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
(1998) · PsycEXTRA Dataset · doi:10.1037/e547602006-001 · Cited by 1,213
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell-Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 672
Alter, M. J. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450170079026 · Cited by 615
Estimating future hepatitis C morbidity, mortality, and costs in the United States
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.10.1562 · Cited by 567
Predictors of patient and graft survival following liver transplantation for hepatitis C
Charlton, M., Seaberg, E., Wiesner, R., Everhart, J., Zetterman, R., Lake, J., Detre, K., & Hoofnagle, J. (1998) · Hepatology · doi:10.1002/hep.510280333 · Cited by 537
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography
Yin, M., Talwalkar, J. A., Glaser, K. J., Manduca, A., Grimm, R. C., Rossman, P. J., Fidler, J. L., & Ehman, R. L. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.06.012 · Cited by 948
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence
Rehermann, B. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39133 · Cited by 531
Rosen, H. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1006613 · Cited by 487
Conjeevaram, H. S., Fried, M. W., Jeffers, L. J., Terrault, N. A., Wiley–Lucas, T. E., Afdhal, N., Brown, R. S., Belle, S. H., Hoofnagle, J. H., Kleiner, D. E., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.008 · Cited by 472
Metadata
- Authors
- Davis, G. L., Albright, J. E., Cook, S. F., & Rosenberg, D. M.
- Venue
- Liver Transplantation
- Published
- 2003-04
- Volume
- 9
- Issue
- 4
- Pages
- 331-338
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2004360699
- Cited by
- 576
- References
- 29
- FWCI
- 23.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Projecting future complications of chronic hepatitis C in the United States. https://app.cochat.ai/papers/10.1053/jlts.2003.50073
- The paper
- Davis, G. L., Albright, J. E., Cook, S. F., & Rosenberg, D. M. (2003). Projecting future complications of chronic hepatitis C in the United States. Liver Transplantation. https://doi.org/10.1053/jlts.2003.50073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.